Tag Archives: Ed Arce

Paratek Pharmaceuticals (PRTK) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Paratek Pharmaceuticals (PRTK – Research Report) on October 18 and set a price target of $27.00. The company’s shares closed last Monday at $3.24, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: Genfit SA (NASDAQ: GNFT), Aquestive Therapeutics Inc (NASDAQ: AQST) and Aslan Pharmaceuticals Ltd (NASDAQ: ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genfit SA (GNFT – Research Report), Aquestive Therapeutics Inc (AQST – Research Report) and Aslan Pharmaceuticals Ltd (ASLN – Research Report) with

H.C. Wainwright Reaffirms Their Buy Rating on Durect Corp (DRRX)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Durect Corp (DRRX – Research Report) today and set a price target of $3.50. The company’s shares closed last Monday at $1.83, close to its 52-week high of $1.88. Arce

H.C. Wainwright Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) on September 5 and set a price target of $17. The company’s shares closed last Monday at $4.07, close to its 52-week low of

H.C. Wainwright Keeps Their Buy Rating on Dicerna Pharma (DRNA)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Dicerna Pharma (DRNA – Research Report) today and set a price target of $22. The company’s shares closed last Monday at $12.77. Arce said: “We have received a number of

H.C. Wainwright Sticks to Its Buy Rating for Nabriva (NBRV)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Nabriva (NBRV – Research Report) on August 16 and set a price target of $7. The company’s shares closed last Monday at $2.28. Arce said: “We employ a rNPV valuation